At FAST, it’s our job to push forward all promising Angelman syndrome (AS) programs, and to ensure that the community has a birds-eye view of the entire landscape. Many of these programs have been, or still are, funded by FAST, but this chart also includes those that aren’t (but are disclosed). The progress made is truly promising.
This pipeline is a snapshot in time as of July 2026, please click on the Live Progress Updates below for the most recent pipeline progress..
Ionis has shared an important update with the Angelman syndrome community about the design of CHAMPION, its Phase 3 clinical trial evaluating ION582 (obudanersen). The
“Guided by input from the Angelman community, REVEAL was intentionally designed to evaluate obudanersen across a broad range of people living with Angelman syndrome, reflecting
Oak Hill Bio has shared a community letter to the Angelman syndrome community with an important update on the next steps of the development of
We found solace and purpose through FAST. Their relentless pursuit of a cure resonated with us, and we started our fundraising journey with them.